Skip to main content

PERSPECTIVE article

Front. Neurol.
Sec. Stroke
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1488018
This article is part of the Research Topic Blood-Based Cellular and Molecular Biomarkers in Acute Ischemic Stroke and Hemorrhagic Stroke - Volume II View all 11 articles

Perspective: Use of protein S100B as a quality assurance marker for endovascular therapy in acute ischemic stroke

Provisionally accepted
Franziska Lieschke Franziska Lieschke 1*Christian Foerch Christian Foerch 1,2
  • 1 Center for Neurology and Neurosurgery, University Hospital Frankfurt, Frankfurt, Hesse, Germany
  • 2 Klinikum Ludwigsburg, Ludwigsburg, Baden-Württemberg, Germany

The final, formatted version of the article will be published soon.

    Mechanical thrombectomy (MT) is a highly effective treatment for ischemic stroke associated with large vessel occlusion. Meanwhile, this complex procedure is broadly used throughout the world in hospitals with different levels of experience. Therefore, practical quality assurance is advised to ensure a high standard of care across the board. In this perspective article, we propose the implementation of measuring serum S100B after MT as a surrogate outcome parameter for the extent of tissue damage as an additional quality indicator for internal and external benchmarking in endovascular therapy. We focus on the analysis of patients, in whom there is a discrepancy between the expected (e.g., based on favorable preconditions) and the actual biomarker outcome. We aim to illustrate the advantages and drawbacks of measuring S100B after MT, reliably depicting the procedure's quality and its use for comparison and identification of "outlier" patients in MT patient cohorts for further process and single case analysis.

    Keywords: Quality Assurance, biomarker, S100B, Acute ischemic stroke, Mechanical thrombectomy

    Received: 29 Aug 2024; Accepted: 09 Jan 2025.

    Copyright: © 2025 Lieschke and Foerch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Franziska Lieschke, Center for Neurology and Neurosurgery, University Hospital Frankfurt, Frankfurt, Hesse, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.